Three sectors. One standard. Operating in 14 countries.
Home/ Sectors/ 01 Manufacturing

ODM & OEM —
built thin,
built fast.

4CF's manufacturing sector specialises in oral dissolved films (ODF) and adjacent thin-form dosage formats. Two captive lines in Korea and a vetted partner network in EU and APAC. From feasibility to commercial supply, all under one technical owner.

FORMATSODF · Buccal strips · Patches
CAPACITY~2.0B units / year
MOQ50,000 units (pilot)
SCALEUp to 100M units / year
STANDARDEU / KR / JP / US cGMP
SUWON · LINE 02 · CASTING REV. 26.04
FILM WEB · 38μm ± 2μm SCALE — 1m WIDTH
01 — Technology

Up to four functional layers laminated below 50μm.

Release liner— 8μm
Backing film— 10μm
API matrix— 18μm
Mucoadhesive— 8μm
Taste-mask— 6μm
0 — 50μm

Co-extruded, not coated.

Our ODF platform is a continuous solvent-cast, co-extruded multilayer. Each functional film — taste-mask, mucoadhesive, API matrix, backing — is laid down in a single pass with sub-micron tolerance, then converted in-line.

That matters because conventional ODFs are limited to a single drug-loaded matrix. We can split the dose across two reservoirs, mask bitter actives behind a flavour layer, and tune disintegration profile from 8s (sublingual) to 4min (buccal sustained).

38μm
Mean total thickness across the standard ODF stack.
Thickness
±2μm
Lot-to-lot tolerance, validated over 36 months of production.
Precision
8 — 240s
Tunable disintegration window across sublingual to buccal modes.
Dissolution
6kDa
Demonstrated peptide loading; select biologics on request.
API class
02 — Capabilities

Six manufacturing programmes, one technical owner.

ID
Format
Application
Capacity
A1
Oral Dissolved FilmStandard 38μm
Pharma · OTC · Nutra
1.2B / yr
RTM
A2
Bilayer ODFDose-split / taste-mask
Pediatric · pharma
280M / yr
RTM
B1
Buccal mucoadhesive stripSustained 4–6 min
Local oral therapy
120M / yr
RTM
C1
Cosmetic mask filmSingle-use peel format
K-beauty · skincare
340M / yr
RTM
D1
Functional food filmVitamins · nutraceutical
Nutrition · supplement
180M / yr
RTM
E1
Transdermal patchReservoir & matrix
CNS · cardiometabolic
Pilot
DEV
03 — Process

From brief to ship — parallel, not sequential.

01 / Brief
Molecule & need
Active properties, target market, format preference, scale.
02 / Formulate
Lab-scale screen
Polymer/plasticiser matrix, taste-mask, disintegration tuning.
03 / Pilot
10–50k pilot batch
First in-spec roll, analytical method, stability initiation.
04 / Scale
Tech transfer
Validation, registration batches, process performance qualification.
05 / Commercial
Routine supply
Serialised packaging, lot release, demand-led batch sizing.
06 / Sustain
Lifecycle support
Variation management, post-market surveillance, line extensions.

Where it's made.

04 — Manufacturing footprint
Captive · HQ line
Suwon
Two ODF casting lines, in-house analytical lab, formulation R&D, pilot conversion. EU + KR cGMP.
1.4Bunits/yr3lines
Captive · pilot & specialty
Cheongju
Pilot & specialty conversion — bilayer ODF, patch matrix, peptide-grade clean rooms.
120Munits/yr2lines
Partner · EU
Basel
Long-standing CDMO partner for EU-bound supply, packaging & serialisation. Swissmedic GMP.
240Munits/yrEUrelease
Partner · Japan
Osaka
Local conversion & PMDA-aligned QA for Japanese OTC and pharma supply.
180Munits/yrJPrelease
Partner · China
Suzhou
NMPA-registered packaging & QA support for greater-China commercial supply.
140Munits/yrCNrelease
Partner · USA
Boston
FDA-registered packaging & warehouse for North American distribution.
60Munits/yrUSrelease